- Home
- INSP vs HTFL Comparison
INSP vs HTFL Comparison
Compare INSP & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INSP | HTFL |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | INSP | HTFL |
|---|---|---|
| Price | $59.81 | $22.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $101.07 | $39.20 |
| AVG Volume (30 Days) | 1.4M | ★ 1.4M |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 179.43 | N/A |
| EPS | ★ 4.89 | N/A |
| Revenue | ★ $82,050,000.00 | N/A |
| Revenue This Year | $8.44 | $40.42 |
| Revenue Next Year | $8.60 | $22.73 |
| P/E Ratio | $12.25 | ★ N/A |
| Revenue Growth | ★ 62.18 | N/A |
| 52 Week Low | $53.11 | $20.13 |
| 52 Week High | $172.95 | $41.22 |
Technical Indicators
Market Signals| Indicator | INSP | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 36.23 | 39.16 |
| Support Level | $57.57 | $20.13 |
| Resistance Level | $84.26 | $32.52 |
| Average True Range (ATR) | 4.10 | 1.54 |
| MACD | 0.85 | 0.14 |
| Stochastic Oscillator | 7.32 | 23.61 |
Price Performance
Historical ComparisonAbout INSP Inspire Medical Systems Inc.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.